SMS Pharmaceuticals Files SEBI Compliance Certificate for Q4 FY26
SMS Pharmaceuticals Limited filed a compliance certificate for the quarter ended March 31, 2026, as per SEBI regulations. The company's RTA confirmed timely dematerialization of securities and compliance with depository procedures.
This is a standard compliance filing required by SEBI, which is a routine activity for listed companies and has no immediate impact on the company's operations or financial performance.
The announcement is a routine regulatory filing and does not contain any information that would positively or negatively impact the company's stock.
SMS Pharmaceuticals Limited has submitted a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended March 31, 2026. This certificate was received from the company's Registrar and Share Transfer Agent, Aarthi Consultants Private Limited. The certificate confirms that the company has complied with the dematerialization of securities within 15 days of receipt from depository participants during the period January 1, 2026, to March 31, 2026. This process involves mutilating and cancelling original certificates, and updating the depository as the registered owner on the stock exchange records.
The submission was made to the BSE Limited and the National Stock Exchange of India Ltd. on April 7, 2026, with the Company Secretary, Thirumalesh Tumma, signing off on behalf of SMS Pharmaceuticals Limited. The Registrar and Share Transfer Agent, Aarthi Consultants Private Limited, has confirmed the actions taken regarding dematerialization, including mutilation and cancellation of certificates and updating the depository's name as the registered owner.
What to do with a filing like this
SMS Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by SMS Pharmaceuticals Limited. Read the original for the full detail.